Dr. Christopher M. Pieczonka, M.D.

Medicare patients and services

Medicare patients, 2024

1,125

Services billed

32,166

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 28 companies reported 216 payments worth $221,774 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 37 industry-funded studies in 2025, from 15 companies. The companies reported $6,436,553 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Pfizer Inc.
• A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
  Janssen Research & Development, LLC
• A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
  AstraZeneca Pharmaceuticals LP
• A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
  Janssen Research & Development, LLC
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232
• Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
  Janssen Research & Development, LLC
• MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-…
  Janssen Research & Development, LLC
• A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
  E.r. Squibb & Sons, L.l.c.
• A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible …
  Janssen Research & Development, LLC
• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Syracuse

• Nicole Ackerman, MD
• David M. Albala, M.D.
• Ilija Aleksic, M.D.
• Joel S. Bass, M.D.
• Elizabeth Bearrick, MD
• Kenneth A. Beasley, MD
• Seetharam Bhat Kulthe Ramesh, MD
• Stephen A. Blakely, MD